For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for GE HealthCare Technologies Inc. (GEHC) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Our current read (analysis of 2026-08-23): Designation Low · Gem Score -20 (−100…+100 Quality+Value blend) · Quality 7 · Value -42 · Sentiment 21 (timing only, not weighted) · Composite fair value $73.70 vs $69.36 at analysis
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
GE HealthCare Technologies Inc.
GEHC NASDAQGE HealthCare Technologies Inc. is a medical technology company that develops and manufactures imaging systems, ultrasound equipment, patient monitoring tools, and pharmaceutical diagnostics. The company serves hospitals, clinics, research institutions, and life sciences organizations with products and digital solutions used in diagnosis, treatment support, and workflow efficiency. Its current business is organized around four segments: Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics. GE HealthCare Technologies Inc. plays a significant role in the healthcare market by supplying equipment and services that support clinical decision-making, procedural guidance, and diagnostic testing across a broad range of medical settings. Headquartered in Chicago, Illinois, the company focuses on technologies that are central to modern medical care and hospital operations.
Price Overview
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 4.55
Total Equity: $10.60B
Shares: 458,000,000
Total Debt: $10.00B
Cash: $4.49B
EBITDA: $3.05B
Total Debt: $10.00B
Cash: $4.49B
Revenue: $20.63B
Revenue: $20.63B
Revenue: $20.63B
Total Equity: $10.60B
Tax Rate: 22.2%
Equity: $10.60B
Total Debt: $10.00B
Cash: $4.49B
Current Liabilities: $9.11B
Long-Term Debt: $9.50B
Total Debt: $10.00B
Total Equity: $10.60B
Shares: 458,000,000
Shares: 458,000,000
CapEx: -$482.00M
Shares: 458,000,000
Stock Price: $69.33
Net Income: $2.08B
Industry Benchmarks
Income Statement (Annual)
Last updated: Aug 3, 2026 12:05pm (20d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $17.6B | $18.3B | $19.6B | $19.7B | $20.6B |
| Cost of Revenue | $10.4B | $11.2B | $11.6B | $11.5B | $12.4B |
| Gross Profit | $7.2B | $7.2B | $7.9B | $8.2B | $8.2B |
| Operating Expenses | $4.4B | $4.7B | $5.5B | $5.6B | $5.5B |
| Operating Income | $2.8B | $2.5B | $2.4B | $2.6B | $2.8B |
| Net Income | $2.2B | $1.9B | $1.6B | $2.0B | $2.1B |
| EBITDA | $3.0B | $2.8B | $2.7B | $2.9B | $3.1B |
| EPS | $4.95 | $4.22 | $3.05 | $4.37 | $4.56 |
| EPS (Diluted) | $4.95 | $4.22 | $3.03 | $4.34 | $4.55 |
Balance Sheet (Annual)
Last updated: Aug 3, 2026 11:34am (20d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | — | $1.4B | $2.5B | $2.9B | $4.5B |
| Total Current Assets | — | $8.3B | $9.4B | $9.9B | $12.5B |
| Total Assets | — | $27.5B | $32.5B | $33.1B | $36.9B |
| Current Liabilities | — | $7.2B | $9.0B | $9.6B | $9.1B |
| Long-Term Debt | — | $8.2B | $8.4B | $7.4B | $9.5B |
| Total Liabilities | — | $17.9B | $25.1B | $24.4B | $26.3B |
| Total Equity | $16.9B | $9.6B | $7.3B | $8.7B | $10.6B |
| Retained Earnings | — | $0 | $1.3B | $3.3B | $5.3B |
Cash Flow (Annual)
Last updated: Aug 3, 2026 12:05pm (20d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $1.6B | $2.1B | $2.1B | $2.0B | $2.0B |
| Capital Expenditure | -$248.0M | -$310.0M | -$387.0M | -$401.0M | -$482.0M |
| Free Cash Flow | $1.4B | $1.8B | $1.7B | $1.6B | $1.5B |
| Acquisitions (net) | -$1.5B | $0 | -$147.0M | -$313.0M | -$378.0M |
| Net Debt Issued / (Repaid) | -$2.0M | $8.2B | $2.0B | $995.0M | $2.7B |
| Dividends Paid | $0 | $0 | -$41.0M | -$55.0M | -$64.0M |
| Stock Buybacks | — | — | $0 | $0 | -$200.0M |
| Net Change in Cash | -$451.0M | $890.0M | $1.1B | $387.0M | $1.6B |
Growth Trends (YoY %)
Last updated: Aug 3, 2026 12:05pm (20d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +4.3% | +6.6% | +0.6% | +4.8% |
| Gross Profit Growth | +0.1% | +10.3% | +3.6% | +0.5% |
| Operating Income Growth | -9.8% | -3.4% | +7.8% | +5.3% |
| Net Income Growth | -14.7% | -18.2% | +27.1% | +4.6% |
| EBITDA Growth | -8.9% | -2.4% | +7.8% | +5.4% |
Dividend History (Last 20)
Last updated: Aug 3, 2026 11:34am (20d ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2026-07-24 | $0.04 | — | — | — |
| 2026-04-02 | $0.04 | — | — | — |
| 2026-01-09 | $0.04 | — | — | — |
| 2025-10-24 | $0.04 | — | — | — |
| 2025-07-25 | $0.04 | — | — | — |
| 2025-04-25 | $0.04 | — | — | — |
| 2025-01-14 | $0.04 | — | — | — |
| 2024-10-18 | $0.03 | — | — | — |
| 2024-07-19 | $0.03 | — | — | — |
| 2024-04-18 | $0.03 | — | — | — |
| 2024-01-12 | $0.03 | — | — | — |
| 2023-10-19 | $0.03 | — | — | — |
| 2023-07-20 | $0.03 | — | — | — |
| 2023-05-22 | $0.03 | — | — | — |
Deep Analysis
Risk : Reward — if the last quarter repeats
Live · as of 2026-08-19 08:53Recovery pays +15%; another quarter like the worst recent one costs 38%. Ratio 0.4:1.
| Case | Growth | Margin | Fair value | vs price ($69.36) |
|---|---|---|---|---|
| Bull — recovery | +8% | 13.4% | $79.50 | +15% |
| Base — stabilizes | +6% | 11.7% | $63.91 | -8% |
| Bear — keeps slipping | +3% | 9.9% | $50.40 | -27% |
| Stress — last quarter repeats | +7% | 6.9% | $42.66 | -38% |
Narrative Economics
market-narrative step).
Claude Reading
The raw quarterly trajectory is less flattering than the synthesis lets on. Q1 2026 revenue of $5.13B is up only 7.3% YoY vs Q1 2025's $4.78B, but net income fell to $389M (7.6% margin) from $564M (11.8%) — a 31% earnings decline in the most recent print. Q4 2025's $588M NI was also down from $721M in Q4 2024. So while the annual 2025 numbers look like modest growth ($20.63B rev, $2.08B NI vs $19.67B/$1.99B), the exit-rate margin picture is deteriorating, not inflecting. The "earnings_cagr 15.3%" in the momentum block is arithmetically true off a depressed 2023 base ($1.57B) but misleading — 2021 NI was $2.25B, so on a 4-year view earnings are actually down. This matters because the synthesis leans on "margin excellence" as the bull pillar.
Balance sheet is fine but not fortress: $10.0B debt against $4.5B cash and $10.6B equity, D/E of 0.94, and FCF of $1.51B against a -6.3% FCF CAGR. That's a stretched leverage profile for a business whose FCF is shrinking, and it constrains buyback capacity — the 0.2% dividend yield and 3% payout ratio are almost rounding errors. ROIC of 13.4% is respectable but not a compounder's number, and the $482M capex against $1.99B OCF shows this is genuinely capital-light for a device maker, which is the one thing I'd underwrite as a durable positive. EV/EBITDA of 11.9x and P/E of 15.2x are cheap versus Siemens Healthineers (~25x) and Stryker (~30x), but those peers are growing 6-9% organically vs GEHC's 2.7% revenue CAGR. The discount is earned, not anomalous.
The models are internally inconsistent in a way worth naming. The synthesis says "market prices in more growth than projected — vulnerable to disappointment" and then delivers a +19% signal-adjusted upside to $82.64. Those two statements don't cohere: if the market is over-pricing growth, fair value should be *below* spot, not 19% above. Market Forces calls "tailwinds" while Secondary Signals flags "Macro Headwinds" — pick one. The insider buying is real (three open-market purchases in May 2026) but small in dollar terms (10,000 + 1,618 + 1,000 shares ≈ $850K at spot), swamped by the award/in-kind activity that's just comp mechanics. I'd characterize this as mild positive signaling, not the "significant insider buying" the secondary tag claims. The narrative layer's read — anchored, minimal intensity, 16% discount reflecting real execution risk — is the most honest framing in the file.
A careful contrarian argues this: GEHC is a post-spinoff medtech with structurally lower growth than its imaging peers because it inherited GE's slower-turnover installed base, its Q1 2026 margin collapse to 7.6% suggests either tariff/input-cost pressure or pricing weakness that management hasn't yet addressed, and hospital capex has been choppy heading into 2026. At 15x earnings you're paying a fair multiple for a 3% grower with deteriorating margins — not a bargain. The bull case requires you to believe (a) AI/software mix genuinely inflects margins back to 13%+, (b) revenue reaccelerates to mid-single-digits, and (c) the spinoff discount closes. None of those are visible in the Q1 print. I dissent from the synthesis's $82.64 target as too generous. Fair value on 14x normalized $2.1B NI is closer to $68-72 — essentially where it trades. The stock isn't expensive, but it isn't the 19% mispricing the composite claims. I'd wait for either the Q2 print confirming margin recovery or a drawdown to the low $60s before committing capital. The insider purchases are a mild tell worth monitoring but not sizing around.
GPT Reading
What stands out is that GE HealthCare is being valued like a low-growth industrial despite having better economics than that label implies, but the recent operating trajectory is not clean enough to call it a clear bargain. Revenue grew from $19.67B in 2024 to $20.63B in 2025, about 4.9%, and the quarterly run-rate keeps that intact: Q1 2026 revenue of $5.13B was up 7.3% from $4.78B a year earlier. That is respectable for a scaled medtech franchise. Gross profit, however, barely moved in 2025 to $8.25B from $8.21B, so gross margin compressed from 41.7% to 40.0% even as operating income improved to $2.76B from $2.63B. That says the earnings story is being held together more by below-gross-line discipline than by pricing power. Net income rose only modestly to $2.08B in 2025 from $1.99B in 2024, and if you annualize the latest quarter’s $389M, you get a much weaker earnings base than the trailing year suggests. The business is stable; the idea that it is already back to a smooth compounding machine is premature.
The quarter pattern reinforces that caution. Q1 2025 posted an 11.8% net margin, but Q1 2026 dropped to 7.6% despite higher sales. Across the last eight quarters, margins have swung between 7.6% and 13.6%, which is more volatility than the “steady compounder” label deserves. The annual numbers also show that 2021 produced $2.25B of net income on $17.59B of revenue, while 2025 produced only $2.08B on $20.63B. In other words, four years of revenue growth have not yet translated into a new profit peak. Cash flow tells a similar story: 2025 free cash flow was $1.51B against $2.08B of net income, a decent but not elite conversion ratio, and operating cash flow of $1.99B is not especially strong for a $30.7B market cap company with $10.0B of debt. Net debt is about $5.5B after backing out $4.49B of cash, so leverage is manageable, but it matters because this is not a business gushing excess cash.
At $69.33, the stock is not expensive. A 15.2x P/E, 1.54x sales, and 11.9x EV/EBITDA for a market-leading diagnostic and care platform company with roughly 40% gross margins, 13.4% operating margins, and nearly 20% ROE is plainly reasonable. On trailing numbers, the market is not paying up for any heroic AI or digital narrative. That said, I do not think the right response is to slap a premium multiple on it just because the absolute valuation looks lower than flashier medtech peers. The low multiple is at least partly earned by the mediocre growth profile, margin inconsistency, and weak free-cash-flow trend. Revenue CAGR of 2.7% is sluggish, and FCF CAGR of -6.3% is a real yellow flag for a company supposed to be a dependable installed-base cash generator. My read is that the stock is modestly undervalued because the balance of franchise quality and current multiple is favorable, but only modestly: this looks more like a $78 stock than a $95 stock.
The best case against that view is straightforward. First, earnings quality may be better than the choppy quarterly net margins suggest, because annual operating income has climbed from $2.44B in 2023 to $2.63B in 2024 and $2.76B in 2025, showing real underlying progress. Second, return metrics are solid: 13.35% ROIC is strong enough to justify more than a market multiple for a healthcare equipment business, and debt-to-equity under 1.0 is not aggressive. Third, insider buying matters here because it is clustered and recent, including a 10,000-share open-market purchase on 2026-05-22 plus smaller buys earlier in May, which is more informative than routine stock awards. If those insiders are buying into a temporary Q1 margin dip caused by mix, timing, or FX rather than a structural issue, then 15x earnings is too cheap and the model-based upside into the low $80s is plausible. I weigh that evidence less heavily because the hard data still say that growth has not yet cleanly converted into better cash generation or sustainably higher margins.
What would change my mind is simple. If the next two quarters hold revenue above $5.1B while net margin returns to at least 9.5%-10%, that would show Q1 2026 was a soft patch rather than a trend, and I would move my fair value into the low-to-mid $80s. If full-year free cash flow can get back toward $1.8B-$2.0B without balance-sheet strain, the stock deserves a higher multiple. On the other hand, if revenue stays in the mid-single digits but quarterly net margin remains stuck around 8% and FCF again trails net income by a wide margin, then the current discount is justified and fair value drops toward the low $60s.
Grok Reading
The numbers paint a post-spinoff franchise that is grinding out mid-single-digit growth while the market refuses to pay for anything more ambitious. Revenue climbed from $19.67B in 2024 to $20.63B in 2025 (+4.9%), and the trailing quarterly run-rate continues to print $5.0–5.7B with a recent year-over-year lift of roughly 5–7%. That is real, if unspectacular, top-line recovery. Net income held near $2.08B annually and ROE sits at a respectable 19.7%, yet the quarterly margin path is the tell that matters: Q1 2026 net margin collapsed to 7.6% ($389M on $5.13B) from 11.8% a year earlier, and Q4 2025 already showed compression versus the prior-year peak. Free-cash-flow generation of $1.51B (FCF yield ~4.9% at the $30.7B market cap) remains solid in absolute terms, but the –6.3% FCF CAGR flags that cash conversion is not tracking the earnings recovery the income statement advertises. At 15.2× earnings, 1.54× sales and 11.9× EV/EBITDA, the stock is priced like a slow industrial rather than a 40% gross-margin medical-device platform with an installed base that must be serviced. Insider open-market purchases totaling more than 12,000 shares in May 2026 reinforce that management sees the same discount.
The valuation synthesis calling for $74–83 fair value is directionally correct but overstates precision; the composite itself admits method disagreement. What the models under-weight is the recent earnings durability problem. Annual NI rose only 4.5% despite the revenue step-up, and the two most recent quarters delivered lower absolute profits than their year-ago counterparts. That pattern is inconsistent with a clean “margin excellence” narrative and more consistent with mix pressure, pricing friction against Siemens/Philips, or residual stranded-cost noise from the GE separation. Debt of $10B against $4.5B cash and $10.6B equity (D/E 0.94) is serviceable given $2B of operating cash flow, yet it leaves limited room for aggressive capital return or transformative M&A if hospital CapEx softens. The 2.7% revenue CAGR over the longer window remains the binding constraint: this is still a mature earner, not a re-acceleration story the market will re-rate on faith.
The strongest counter-argument is straightforward: if Q1 margin compression proves transitory and revenue holds the 5%+ pace, then 15× earnings on a business throwing off $1.5B-plus of FCF with a sticky imaging and monitoring installed base is simply too cheap relative to device peers. A smart opponent would also note that earnings CAGR of 15% over the measured period already embeds meaningful operating leverage, that the spinoff discount is a known and fading overhang, and that significant insider buying is rarely a coincidence at these levels. Those points have force; I simply weigh the sequential profit decline and negative FCF trend more heavily until two clean quarters reverse them. The narrative layer correctly identifies minimal cult premium and an anchored, mildly pessimistic story—exactly the setup where multiple expansion requires proof, not promises.
Two consecutive quarters of net margins back above 10% with revenue growth sustained above 5%, or a clear acceleration in FCF that reverses the multi-year decline, would flip me from cautious buyer to aggressive. Conversely, another sub-8% margin print or hospital CapEx commentary that knocks the growth rate back under 3% would push the stock toward fairly valued at best around the low $60s.
Big-3 Panel — where each AI stands
Advanced Analysis Forensic deep-dive · separate lenses
GEHC is a real business: revenue has grown steadily from $17.6B (2021) to $20.6B (2025), a ~4% CAGR, with gross margins parked in a tight 39-42% band and operating margins in the 12.5-15.9% zone. Free cash flow has run $1.5-1.8B annually and OCF/NI of 1.02x with accruals at -0.5% of assets says reported earnings are backed by cash. Share count is essentially flat (454M to 458M over five years) and SBC is a modest 0.6% of revenue - per-share value is not being leaked out the back door. Insider behavior corroborates: seven open-market purchases totaling $6.2M in the last twelve months, zero sales, including a $642K buy by Lobo and buys by Hochman and Yang Watkin - directors and officers putting personal cash in. The concerns are structural rather than acute. Net debt of ~$5.5B against $4.5B liquid cash and an Altman Z of 1.82 (grey zone) means the balance sheet is a constraint, not a cushion - fine while FCF holds, uncomfortable if it doesn't. Operating margin has compressed from 15.9% (2021) to 13.4% (2025) even as gross margin held; something in opex/mix is eating the leverage a growing device franchise should throw off. Net income in 2025 ($2.08B) is still below the 2021 print ($2.25B) despite $3B more revenue. Buybacks only recover 39% of SBC dilution, so capital return to holders is minimal. Net read: a durable, self-funding earner with honest accounting and disciplined share issuance, but not a fortress - leverage and flat-to-down profitability keep it out of the top tier.
Verify before trusting this (5)
- Segment mix and pricing/cost drivers behind the 250bps OpM compression 2021-2025
- Debt maturity ladder and covenants given $5.5B net debt position
- Customer/geographic concentration (hospital systems, China exposure) from 10-K
- Whether the GE spin left any residual indemnity or pension obligations
- R&D as % of revenue trend and pipeline vs. Philips/Siemens Healthineers competitive position
The composite fair value sits at $73.77 against a $69.36 price, a ~6% gap that is well inside normal modeling noise. The signal-adjusted $82.64 (~19% upside) leans on the anchored-PE method at $122.62, which looks like a runaway output relative to the DCF ($58.24) and EPV floor ($55.97) - both of which sit BELOW today's price. Two of three methods say the stock is already at or slightly above intrinsic; only the multiple-based method argues for meaningful upside, and that method implicitly assumes the historical earnings power returns despite the observed operating-margin drift.
Verify before trusting this (4)
- Operating margin trajectory in next 2 quarters - is the drift stabilizing or accelerating
- Service/recurring revenue mix disclosure to validate the compounder thesis
- Debt paydown pace and interest expense guidance
- Any one-time items inflating the anchored-PE input
The macro backdrop is mildly constructive - neutral regime, VIX at 16, S&P barely off highs - and for a low-beta (0.84) medical device name that translates into almost no tape drag. GEHC is exactly the profile that benefits from a boring market: defensive healthcare cash flows, recurring service revenue, and no meme-status exposure to rate or risk-off shocks. The 4.68% 10y is a generic overhang for all equities, but it lands softly on a stock the market treats as a bond-like compounder rather than a growth story. The active narrative is a durable 'steady-compounder' with minimal intensity and low cult coefficient - meaning there is no froth to unwind and no hot story to break. The recent news flow directly feeds that narrative: a Q2 beat with record backlog and book-to-bill, a strategic review of the underperforming Patient Care Solutions segment (a classic sentiment-positive portfolio cleanup signal), and a new AI-enabled breast imaging product launch. These are the small, drip-fed positives that reinforce a compounder story rather than ignite it. Nothing here is euphoric; nothing here is breaking. Net pressure is a modest, steady tailwind - the tape is not fighting this name and the narrative is quietly being validated by execution.
Verify before trusting this (4)
- Analyst target revisions post-Q2 - are they nudging up on the backlog print?
- Outcome and timing of the Patient Care Solutions strategic review (sale vs spinoff vs hold)
- Any sector rotation into defensive healthcare or out of medtech as rate expectations shift
- Whether Siemens Healthineers or Philips post competing results that reframe the competitive narrative
This lens hasn't been run for this ticker yet.